An interventional study of Urodynamic evaluation before and after solifenacin treatment. and Urodynamic evaluation before and after mirabegron treatment. in Overactive Bladder (OAB), sponsored by Mackay Medical College. Recruiting at 1 site in Taiwan. Open to female participants aged 30 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-06-17.
Sponsored by Mackay Medical College · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive — 3 open to participants now, 5 under way, 1 of them phase 3. botulinum toxin type A · Urinary Bladder, Overactive.
Among the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive, this one is the 27th largest by planned enrollment, is the only one that started in 2025, is one of 2 with no phase, and was the 44th registered.
861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.
Browse Urinary Bladder, Overactive studies →3 of the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive are open now, in 2 countries. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Women only
Walter Reed National Military Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 30 Years to 100 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13 · Phase 3 18 · Phase 4 10
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 70 across 652 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 84 across the 44 interventional studies. Of the 32 that completed or were terminated, 21 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 44 have an industry lead sponsor. The 10 most frequent:
Mackay Medical College is the lead sponsor of 20 studies on the registry; 8 are open to participants now.
Mackay Medical College has 1 study filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing botulinum toxin type A in Urinary Bladder, Overactive, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Overactive bladder (OAB) syndrome is a prevalent condition that significantly impairs patients' quality of life. Standard therapeutic strategies include oral antimuscarinics (e.g., solifenacin), beta-3 adrenergic agonists (e.g., mirabegron), and intradetrusor injection of botulinum neurotoxin type A (BoNTA). Despite their clinical utility, these treatments share a common mechanism of action: suppression of detrusor muscle contractility. However, it remains unclear whether such suppression translates to a reduction in the overall mechanical work output of the bladder during micturition.
To address this question, our research proposes to assess how mirabegron, solifenacin, and BoNTA influence bladder function from a thermodynamic perspective. We will apply pressure-volume analysis (PVA), a methodology traditionally used in cardiac physiology, to quantify the mechanical work performed by the bladder per voiding cycle. This approach enables a direct measurement of the energy expenditure required for bladder emptying, offering insights beyond standard urodynamic parameters.
Furthermore, emerging data suggest BoNTA may exert additional effects beyond parasympathetic inhibition. Specifically, recent studies have demonstrated that BoNTA also inhibits norepinephrine release from sympathetic hypogastric nerve terminals. Since modulation of sympathetic activity-particularly via the hypogastric nerve-has been implicated in regulating bladder compliance and storage function, we hypothesize that BoNTA may influence bladder compliance through this secondary mechanism. To explore this, we will employ volume-pressure analysis (also abbreviated as PVA), which graphically represents the dynamic relationship between bladder volume and pressure throughout voiding cycles, thus capturing real-time changes in compliance.
Comparative studies of mirabegron, solifenacin, and BoNTA will allow us to differentiate their respective impacts on bladder work and compliance. Mirabegron, which selectively activates beta-3 adrenergic receptors, has minimal influence on overall sympathetic tone. In contrast, solifenacin not only antagonizes muscarinic receptors but may also indirectly potentiate sympathetic tone by reducing parasympathetic influence. BoNTA, with its dual action on both autonomic pathways, provides a unique model to dissect these neural mechanisms.
To extend our findings from clinical observations to preclinical validation, we aim to develop and utilize a spinal cord injury (SCI) rat model that recapitulates the bladder dysfunction observed in neurogenic detrusor overactivity (NDO)-a condition for which mirabegron, solifenacin, and BoNTA are also commonly prescribed. By applying both thermodynamic and compliance-focused PVA techniques in this animal model, we seek to construct a foundational database characterizing how these drugs modulate bladder function in a controlled, reproducible setting.
In summary, this project integrates a novel application of pressure- and volume-based analyses to quantify the mechanical and compliance-related effects of established OAB therapies in both human patients and a translational animal model. The findings will provide new mechanistic insights into how these treatments alter bladder physiology, potentially guiding future therapeutic strategies and optimizing drug selection for individualized patient care.
BACKGROUND:
Year 1. Overactive bladder (OAB) syndrome remarkably places a burden on patients' quality of life. Given options for OAB therapies, namely oral anti-muscarinics, oral beta-3 agonists, and intra-detrusor botulinum neurotoxin type A (BoNTA) injection, involve trimming down of detrusor contractility, we wonder, if these modalities would diminish thermodynamic work performed by bladder. For this purpose, the impact of mirabgreon, solifenacin, and BoTNA on the work expenditure of bladder of OAB patients will be investigated using pressure-volume analysis (PVA), a protocol that thermodynamically quantifies work done by the bladder per voiding cycle.
Year 2. In addition to the well-established action, i.e., to impede acetylcholine release from the parasympathetic pelvic nerve, BoNTA also inhibits norepinephrine release from the ending of sympathetic hypogastric nerve. As a very recent work has linked adapted hypogastric tone to bladder compliance increment in patients with stress urinary incontinence, we wonder if via altering the activity of hypogastric nerve, intra-detrusor BoNTA injection would modify compliance to impact storage function of the bladder. Hence, effects of mirabgreon (a drug barely affecting sympathetic tone), solifenacin (a drug potentiating sympathetic tone), and BoTNA on the compliance dynamics of OAB patients' bladder will be investigated using volume-pressure analysis (PVA), a protocol that graphically illustrate compliance dynamics of voiding cycles.
YEAR 3: Developing an animal model available for testing pharmacological and side effects of mirabgreon, solifenacin, and BoTNA would offer a platform bridging preclinical experiments to clinical trial. Because above therapies are also prescribed in the therapy for neurogenic detrusor overactivity (NDO) patients; moreover, spinal cord injury (SCI) has been well-accepted as an animal model mimicking the condition of NDO. We therefore, aim to establish database of the impact of mirabgreon, solifenacin, and BoTNA on the thermodynamic work and compliance dynamics of NDO-like rats using the SCI model.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
oral solifenacin
Drug: Urodynamic evaluation before and after solifenacin treatment.
oral mirabegron
Drug: Urodynamic evaluation before and after mirabegron treatment.
oral Solifenacin and mirabegron
Drug: Urodynamic evaluation before and after combined treatment with solifenacin and mirabegron.
Botox injection
Drug: Urodynamic evaluation before and after Botulinum toxin (Botox) injection.
Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
Drug page: Botulinum toxin type AStudies of Botulinum toxin type ABotulinum toxin type A pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Cystometry performed at 1 month before and 1, 6 months following/after treatments will be analyzed.
pressure-volume analysis
urine leakage.
Time frame: within a voiding cycle (a cycle is about 30 to 60 minutes) 1-4 weeks before and 6-12 month after the operation
volume-pressure analysis
urine leakage.
Time frame: within a voiding cycle (a cycle is about 30 to 60 minutes) 1-4 weeks before and 6-12 month after the operation
Start is estimated for Jul 2025; primary completion for May 2026, 10 months later.
Of 135 non-industry interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 10 months is below that.
Counting every sponsor, half of 176 studies reached it within 19 months; a quarter within 10 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A
Mackay Medical College